Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine☆

Bärnighausen, Till; Bloom, David E.; Canning, David; Friedman, Abigail S; Levine, Orin S.; O’Brien, Jennifer; Privor-Dumm, Lois; Walker, Damian

doi:10.1016/j.vaccine.2010.11.090

Cited by 102 publications

(81 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hib vaccination can avert long-term neurological sequelae of Hib infection, such as deafness, blindness, mental retardation, seizures, and paralysis, which affect a child's ability to attend school and to learn (18,24,25,30). Avoiding meningitis-related long-term disability through vaccination could result in averting very large productivity losses (estimated at up to US$ 910 million over a ten-year period in 72 low-income countries) (54).…”

Section: Community Health Externalitiesmentioning

confidence: 99%

“…Herd effects: studies have documented marked reductions in the incidence of Hib infection in unvaccinated persons following the introduction of Hib vaccine into national immunization programs (18,45,47). Hib vaccination can prevent disease and thus obviate the need for antibiotic use, reducing the prevalence of antibiotic-resistant strains (18,48).…”

Section: Community Health Externalitiesmentioning

confidence: 99%

“…Hib vaccination can prevent disease and thus obviate the need for antibiotic use, reducing the prevalence of antibiotic-resistant strains (18,48).…”

Section: Community Health Externalitiesmentioning

confidence: 99%

“…Despite the potential importance of the broad benefits of vaccination at the individual and population levels, recent reviews of the literature reveal that many of these benefits are typically neglected in economic evaluations of vaccination (18,50,51). The existing reviews on this topic contribute two major findings: First, only a small portion of existing economic evaluation studies takes a broad view of the benefits of vaccination, and even those that do are relatively confined in how far they go beyond the narrow benefit here were little data on long-term and societal economic benefits such as morbidity-related productivity gains, averting catastrophic health expenditures, growth in gross domestic product (GDP), and economic implications of demographic changes resulting from vaccination" (51).…”

Section: Value Of Vaccination: Building the Evidence Basementioning

confidence: 99%

See 3 more Smart Citations

Valuing vaccination

Bärnighausen

Bloom

Cafiero-Fonseca

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

166

149

View full text Add to dashboard Cite

Vaccination has led to remarkable health gains over the last century. However, large coverage gaps remain, which will require significant financial resources and political will to address. In recent years, a compelling line of inquiry has established the economic benefits of health, at both the individual and aggregate levels. Most existing economic evaluations of particular health interventions fail to account for this new research, leading to potentially sizable undervaluation of those interventions. In line with this new research, we set forth a framework for conceptualizing the full benefits of vaccination, including avoided medical care costs, outcome-related productivity gains, behavior-related productivity gains, community health externalities, community economic externalities, and the value of risk reduction and pure health gains. We also review literature highlighting the magnitude of these sources of benefit for different vaccinations. Finally, we outline the steps that need to be taken to implement a broad-approach economic evaluation and discuss the implications of this work for research, policy, and resource allocation for vaccine development and delivery.benefit-cost analysis | immunization

show abstract

Section: Community Health Externalitiesmentioning

confidence: 99%

Section: Community Health Externalitiesmentioning

confidence: 99%

“…Hib vaccination can prevent disease and thus obviate the need for antibiotic use, reducing the prevalence of antibiotic-resistant strains (18,48).…”

Section: Community Health Externalitiesmentioning

confidence: 99%

Section: Value Of Vaccination: Building the Evidence Basementioning

confidence: 99%

See 2 more Smart Citations

Valuing vaccination

Bärnighausen

Bloom

Cafiero-Fonseca

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

166

149

View full text Add to dashboard Cite

show abstract

“…This stand in contrast to 1999-2000 rates of 55 cases per 100 000 population amongst <1 year olds [80]. Efficacy has been shown locally in both outcome-related-as well as behaviour-related productivity gains, and use is therefore advocated [84], however contradictory views do exist [85,86].…”

Section: Local Availability and Use Of Combination Vaccines In The Somentioning

confidence: 99%

Combination vaccines in the South African setting

Visser

Hoosen

2012

Vaccine

View full text Add to dashboard Cite

Abstract:The number of vaccines available and included as part of the national immunization schedules, has increased significantly over the past few decades. This impacts on patient/parent compliance and creates a challenge for health care providers for implementation of schedules necessitating training and infrastructure improvements. Use of combination rather than component vaccines offers advantages for compliance by single dose administration of various antigens, reducing stock costing as well as reducing cost of additional health care visits. Combination vaccines are often significantly more expensive than individual constituent vaccines.

show abstract

Semisynthetic Glycoconjugates as Potential Vaccine Candidates Against Haemophilus influenzae Type a

Kohout,

Del Bino,

Petrosilli

et al. 2024

Chemistry A European J

View full text Add to dashboard Cite

Glycoconjugate vaccines are based on chemical conjugation of pathogen‐associated carbohydrates with immunogenic carrier proteins and are considered a very cost‐effective way to prevent infections. Most of the licensed glycoconjugate vaccines are composed of saccharide antigens extracted from bacterial sources. However, synthetic oligosaccharide antigens have become a promising alternative to natural polysaccharides with the advantage of being well‐defined structures providing homogeneous conjugates. Haemophilus influenzae (Hi) is responsible for a number of severe diseases. In recent years, an increasing rate of invasive infections caused by Hi serotype a (Hia) raised some concern, because no vaccine targeting Hia is currently available. The capsular polysaccharide (CPS) of Hia is constituted by phosphodiester‐linked 4‐β‐d‐glucose‐(1→4)‐d‐ribitol‐5‐(PO4→) repeating units and is the antigen for protein‐conjugated polysaccharide vaccines. To investigate the antigenic potential of the CPS from Hia, we synthesized related saccharide fragments containing up to five repeating units. Following the synthetic optimization of the needed disaccharide building blocks, they were assembled using the phosphoramidite approach for the installation of the phosphodiester linkages. The resulting CPS‐based Hia oligomers were conjugated to CRM197 carrier protein and evaluated in vivo for their immunogenic potential, showing that all glycoconjugates were capable of raising antibodies recognizing Hia synthetic fragments.

show abstract

Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine☆

Cited by 102 publications

References 82 publications

Valuing vaccination

Valuing vaccination

Combination vaccines in the South African setting

Semisynthetic Glycoconjugates as Potential Vaccine Candidates Against Haemophilus influenzae Type a

Contact Info

Product

Resources

About